TransThera Sciences (Nanjing), Inc.
藥捷安康(南京)科技股份有限公司
(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 2617)

VOLUNTARY ANNOUNCEMENT

INCLUSION OF YOCHANRA® (TINENGOTINIB) IN THE CSCO GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF BILIARY TRACT CANCERS (2026)

This announcement is made by TransThera Sciences (Nanjing), Inc. (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business advancement of the Group.

The board of directors (the "**Board**") of the Company hereby announces that, the Guidelines for the Diagnosis and Treatment of Biliary Tract Cancers of the Chinese Society of Clinical Oncology (CSCO) (the "**Guidelines**") has been officially released, and YOCHANRA® (tinengotinib), an innovative multi-target small molecule kinase inhibitor self-developed by the Company, has been included in the Guidelines as a Class II recommendation Class 2A for the treatment of advanced biliary tract cancers.

Tinengotinib obtained conditional marketing approval in China on 6 August 2026 for the treatment of adult patients with unresectable advanced or metastatic cholangiocarcinoma (CCA) harboring fibroblast growth factor receptor (FGFR) 2 fusion or rearrangement, who have received prior systemic therapy and FGFR inhibitor treatment. As the first approved therapeutic drug for this indication in China, tinengotinib is expected to benefit FGFR-altered CCA patients who have developed drug resistance, and fill the guideline gap for advanced biliary tract cancers. Tinengotinib was included in the relevant CSCO diagnosis and treatment guidelines just over a month after receiving marketing approval, fully reflecting the presence of substantial unmet clinical needs. The inclusion into the Guidelines will assist clinicians nationwide in gaining a more comprehensive and in-depth insight into the clinical therapeutic value of tinengotinib, thereby promoting a faster and more widespread clinical application of this drug, and benefiting a wider range of patients, which ultimately improves and benefits the patient survival.

Meanwhile, the efficacy data of tinengotinib in combination with atezolizumab in the treatment of patients with advanced biliary tract tumors who have received prior immunotherapy has also been written into the Guidelines in the form of "annotations". A pivotal Phase Ib/II clinical study of tinengotinib in combination with atezolizumab showed that efficacy was observed in patients with advanced biliary tract tumors who have received prior immunotherapy, particularly in FGFR wiled-type patients, with an ORR of 27.8%, a mDOR of 5.7 months, and a DCR of 77.8% in FGFR wiled-type patients, suggesting that its immune activation mechanism has the potential to be independent of FGFR mutation status, providing clinicians and patients with new treatment options for reference.

The global CCA drug market size reached USD2.0 billion in 2024 and is expected to grow to USD3.2 billion in 2027, of which approximately 25.2% of CCA patients have FGFR alterations. According to a research paper published in Cancer Treat Reviews in 2023, CCA patients will develop acquired resistance after receiving FGFR inhibitor treatment. Currently, a Phase III confirmatory clinical study is being conducted in the PRC for tinengotinib versus chemotherapy in patients with CCA. Meanwhile, a global multi-center registrational Phase III clinical trial of tinengotinib for the treatment of patients with advanced CCA has completed enrollment of all subjects.

About Tinengotinib

Tinengotinib is a self-developed innovative multi-target small molecule kinase inhibitor approved for marketing in the PRC targeting FGFR, JAK, VEGFR and Aurora, which exerts anti-tumor effects by precision targeting, lineage reprogramming and immune activation. Currently, tinengotinib has been approved for marketing in the PRC for its first indication, CCA, and multiple clinical trials have been conducted globally for solid tumors such as CCA, prostate cancer, breast cancer and liver cancer. It has been granted Orphan Drug Designation and Fast Track Designation by the U.S. FDA for the treatment of CCA, and Orphan Drug Designation by the EMA in Europe for the treatment of biliary tract cancers.

Warning under Rule 18A.08(3) of the Listing Rules: There is no assurance that the relevant products will ultimately be successfully developed and marketed by the Company.

By order of the Board
TransThera Sciences (Nanjing), Inc.
藥捷安康(南京)科技股份有限公司
Dr. Frank Wu
Chairman and Chief Executive Officer

Hong Kong, 18 September 2026

As at the date of this announcement, the Board comprises: (i) Dr. Frank Wu and Mr. Wu Di as executive directors; (ii) Ms. Jia Zhongxin as a non-executive director; and (iii) Ms. Chui Hoi Yam, Mr. Feng Weibo and Mr. Li Shu Pai as independent non-executive directors.